mTORC1 shutdown unleashes TFEB to drive triple-negative breast cancer invasion

: Gounis, Michalis; Hamidi, Hellyeh; Ivaska, Johanna

Publisher: Elsevier BV

: CAMBRIDGE

: 2025

: Developmental Cell

: DEV CELL

: 60

: 7

: 979

: 981

: 3

: 1534-5807

: 1878-1551

DOI: https://doi.org/10.1016/j.devcel.2025.03.006

: https://doi.org/10.1016/j.devcel.2025.03.006

The PI3K/AKT/mTOR pathway is considered a key therapeutic target in triple-negative breast cancer (TNBC). In this issue of Developmental Cell, Remy et al. challenge this idea by demonstrating that mTORC1 inhibition activates TFEB, promoting MT1-MMP exocytosis, ECM degradation, and increased cell invasion, especially when combined with chemotherapy.